Next Science Limited (NXS) 2019年年度报告「ASX」.pdf

《Next Science Limited (NXS) 2019年年度报告「ASX」.pdf》由会员分享，可在线阅读，更多相关《Next Science Limited (NXS) 2019年年度报告「ASX」.pdf（76页珍藏版）》请在三个皮匠报告上搜索。

1、NEXT SCIENCE LIMITED ACN 622 382 549ANNUAL REPORT YEAR ENDED 31 DECEMBER 201916 Contents 3CONTENTs01OUR PURPOsE402OVERVIEW503CHAIRMANs LETTER 604MANAGING DIRECTORs REPORT705OUR JOURNEY806DIRECTORs REPORT1107LEAD AUDITORs INDEPENDENCE DECLARATION2708CONsOLIDATED sTATEMENT OF PROFIT OR LOss AND OTHER

2、COMPREHENsIVE INCOME2809CONsOLIDATED sTATEMENT OF FINANCIAL POsITION2910CONsOLIDATED sTATEMENT OF CHANGEs IN EQUITY3011CONsOLIDATED sTATEMENT OF CAsH FLOWs3212NOTEs TO FINANCIAL sTATEMENTs3413DIRECTORs DECLARATION 6514INDEPENDENT AUDITORs REPORT6615INVEsTOR INFORMATION7216CORPORATE DIRECTORY75010713

3、02081415030904100511061216 our PurPose 401 OUR PURPOsE01 OUR PURPOsE“Our purpose at Next Science is to heal patients and save lives by addressing the impacts of biofilms on human health,and to commercialise our Xbio technology platform for shareholders.We have a unique opportunity to change the traj

4、ectory of the war on infection by providing solutions that eliminate biofilms,and their incumbent bacteria,fungi and viruses.”02 overview 5Utilising a novel patented technology platform(Xbio),Next Science(ASX:NXS)is bringing to market a portfolio of products to eliminate biofilms and their incumbent

5、 bacteria,fungus and viruses that are often the cause of chronic infections in humans.With some products already approved in certain markets,Next Science has provided answers for more than 130,000 patients by the end of 2019 using products designed for use in:Prosthetic Joint Infection Treatment of

6、Chronic Wounds Treatment of Acne Prevention of Surgical Site infection HEAR ABOUT sOME OF OUR CLINICIANs AND PATIENTs EXPERIENCEsThe strategic growth of Next Science will come from a combination of broadening the product portfolio to:more applications including more prevention products,widening our